Compare PROK & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROK | ALTI |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 409.8M |
| IPO Year | 2021 | 2021 |
| Metric | PROK | ALTI |
|---|---|---|
| Price | $1.65 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 988.6K | 202.5K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.11 |
| EPS | ★ N/A | N/A |
| Revenue | $893,000.00 | ★ $254,956,000.00 |
| Revenue This Year | N/A | $18.06 |
| Revenue Next Year | N/A | $10.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1075.00 | 23.21 |
| 52 Week Low | $0.54 | $2.77 |
| 52 Week High | $7.13 | $5.45 |
| Indicator | PROK | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 44.49 |
| Support Level | $1.55 | $2.96 |
| Resistance Level | $2.59 | $3.93 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.43 | 41.10 |
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.